---
schema_version: "secwatch.filing_event.v1"
accession: "0001411690-25-000003"
form_type: "8-K"
ticker: "BNGO"
cik: "0001411690"
company_name: "Bionano Genomics, Inc."
filed_at: "2025-01-13T23:59:59+00:00"
generated_at: "2026-05-28T03:03:32.110633+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "medium"
source: SEC EDGAR
---

# Bionano reports preliminary Q4 rev $7.9-8.1M (down ~25% YoY); FY rev $30.5-30.7M (down ~15%)

## Summary
- Preliminary Q4 2024 revenue $7.9-8.1M, down ~25% from Q4 2023 due to discontinued clinical service products.
- Full year 2024 revenue $30.5-30.7M, down ~15% from FY2023; excluding discontinued services, core revenue ~$29M, roughly flat.
- OGM installed base 371 units at year-end, up 14% from 326 at end of 2023; flowcell sales 8,058, up 1% YoY.
- Cash, equivalents and AFS securities $20.9M as of Dec 31, 2024; raised $10M gross via registered direct offering in Jan 2025.
- Annualized operating costs reduced by ~$100M since May 2023; senior secured convertible debenture terms modified to lower monthly payments.

## SEC filing metadata
- accession: 0001411690-25-000003
- form_type: 8-K
- ticker: BNGO
- cik: 0001411690
- company_name: Bionano Genomics, Inc.
- filed_at: 2025-01-13T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: medium
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1411690/000141169025000003/0001411690-25-000003-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1411690/000141169025000003/bngo-20250113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001411690-25-000003
- JSON: https://secwatch.observer/filing/0001411690-25-000003.json
- Plain text: https://secwatch.observer/filing/0001411690-25-000003.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.